On November 7, 2019 Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, reported that it will host an analyst & investor breakfast on November 15th from 8:00am to 10:00am ET in New York City (Press release, Molecular Templates, NOV 7, 2019, View Source [SID1234550710]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The meeting will feature presentations by Key Opinion Leaders (KOLs) Matthew McKinney, MD, from Duke University, and Zev Wainberg, MD, from UCLA, who will discuss the current treatment landscape and unmet medical need in treating patients with diffuse large B-cell lymphoma and HER2-positive cancers, respectively. Additionally, John Newcomb, PhD, Director in the Immuno-Oncology Drug Discovery Unit at Takeda Pharmaceuticals, will discuss partnered asset TAK-169, a 2nd generation de-immunized ETB targeting CD38 in multiple myeloma. All of the speakers will be available to answer questions at the conclusion of the event.
The event will also feature a presentation by Molecular Templates’ management team, who will provide an overview of the Company’s R&D pipeline and updates on key clinical programs.
Discussion topics will cover:
MTEM corporate overview provided by Eric Poma, PhD, CEO & CSO of MTEM
Matthew McKinney, MD, will present the current treatment outlook for diffuse large B-cell lymphoma (DLBCL)
MTEM’s CMO, Roger Waltzman, MD, will review the company’s lead program, MT-3724, an ETB targeting CD20, that is being developed for the treatment of DLBCL
John Newcomb, PhD, will review TAK-169 targeting CD38 in multiple myeloma
Zev Wainberg, MD, will discuss the current treatment landscape for HER2-positive cancers
This event is intended for institutional investors and sell-side analysts only. Please RSVP in advance if you plan to attend, as space is limited. For those unable to attend in person, a live webcast and replay will be accessible via the News & Events page on the Investor Relations tab of the Molecular Templates website or by clicking here.
KOL Biographies
Matt McKinney, MD, is an Assistant Professor of Medicine at the Duke University School of Medicine. He specializes clinically in lymphomas and the majority of his clinical practice involves the care of patients with aggressive lymphomas such as diffuse large B cell lymphoma. Additionally, he focuses a significant amount of his effort on clinical and translational research involving novel therapeutics and the use of genomics to guide therapy and improve prognostic models in non-Hodgkin’s lymphomas. He has been the recipient of several awards for his research and clinical work and he has published research in many well respect peer-reviewed journals including Nature Genetics, Cancer Discovery, Journal of Experimental Medicine, and Clinical Cancer Research.
Zev Wainberg, MD, received his medical degree from Tel Aviv University Sackler School of Medicine, New York Program, in 2000. He did his internship and residency in Internal Medicine at Montefiore Medical Center Moses Division Hospital, Albert Einstein College of Medicine, from 2000-2003. He completed his three-year fellowship in Hematology Oncology from the David Geffen School of Medicine at UCLA in 2006. He is the Co-director of the UCLA Gastro-Intestinal Oncology Program and the medical director of the UCLA Colorectal Cancer Center. His research involves a variety of clinical trials in multiple gastrointestinal cancers including pancreas, colon, gastric, and esophageal. Dr. Wainberg’s laboratory-based research involves the testing of novel therapeutics against all gastrointestinal cancers. Currently, he is the recipient of several grants focused on the targeting of cancer stem cells and in molecular classification of GI cancers.